Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.03 million for the quarter.
Inovio Pharmaceuticals Price Performance
INO traded up $0.04 on Friday, reaching $1.98. 540,598 shares of the stock were exchanged, compared to its average volume of 934,290. The company's 50-day moving average price is $2.02 and its 200 day moving average price is $4.29. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The firm has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89.
Analyst Ratings Changes
INO has been the subject of a number of research reports. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright decreased their price objective on Inovio Pharmaceuticals from $5.00 to $3.00 and set a "neutral" rating for the company in a report on Monday, January 13th. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a report on Monday, November 18th. Finally, Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $12.40.
View Our Latest Analysis on Inovio Pharmaceuticals
About Inovio Pharmaceuticals
(
Get Free Report)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
See Also
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
